| scholarly article | Q13442814 |
| P2093 | author name string | Suleiman J | |
| Baraldi E | |||
| Llanos-Cuentas A | |||
| de Wet N | |||
| Della Negra M | |||
| Diekmann-Berndt H | |||
| Krantz EF | |||
| P2860 | cites work | A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 |
| Echinocandins: a new class of antifungal | Q28201851 | ||
| In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi | Q28343817 | ||
| Echinocandin antifungal drugs | Q29398696 | ||
| Some Methods for Strengthening the Common χ 2 Tests | Q30051378 | ||
| Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent | Q33980499 | ||
| Antifungal use in HIV infection | Q34519212 | ||
| Invasive oesophageal candidiasis: current and developing treatment options | Q35109119 | ||
| Options for the management of mucosal candidiasis in patients with AIDS and HIV infection | Q40827662 | ||
| Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. | Q41736571 | ||
| Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin | Q44136245 | ||
| A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis | Q44166464 | ||
| In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis | Q44235810 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| candidiasis | Q273510 | ||
| fluconazole | Q411478 | ||
| esophageal candidiasis | Q5398631 | ||
| P304 | page(s) | 842-849 | |
| P577 | publication date | 2004-08-27 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients | |
| P478 | volume | 39 |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q36601954 | A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis |
| Q35076974 | A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis |
| Q46414215 | A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. |
| Q83820684 | A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation |
| Q33816237 | Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases |
| Q36822941 | Anidulafungin in the treatment of invasive fungal infections |
| Q36505508 | Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents |
| Q37161793 | Antifungal therapies in the intensive care unit |
| Q37763928 | Antifungals to treat Candida albicans |
| Q35557331 | Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal |
| Q26863344 | Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q33830384 | Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. |
| Q36968140 | Clinical pharmacology of antifungal agents in pediatric patients |
| Q34936576 | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. |
| Q28273738 | Comparison of echinocandin antifungals |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q56934885 | Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins |
| Q36623050 | Developments in the treatment of candidiasis: more choices and new challenges |
| Q37889382 | Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy |
| Q41676735 | Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. |
| Q46836740 | Early clinical experience with anidulafungin at a large tertiary care medical center |
| Q36441524 | Echinocandin antifungals: review and update |
| Q37718385 | Echinocandin pharmacodynamics: review and clinical implications. |
| Q39458862 | Echinocandins in antifungal pharmacotherapy. |
| Q28262565 | Echinocandins in the management of invasive fungal infections, part 1 |
| Q41066834 | Echinocandins: A ray of hope in antifungal drug therapy |
| Q34019188 | Echinocandins: the newest class of antifungals |
| Q35515892 | Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs |
| Q40313049 | Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders |
| Q46772887 | Efficacy of micafungin for the treatment of candidemia |
| Q37961230 | Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy--status quo. |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q35097956 | Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013 |
| Q62241543 | Fungal infection in solid organ recipients |
| Q37305399 | Gastrointestinal complications of oncologic therapy |
| Q35073614 | Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q33451088 | In vitro antifungal activity of micafungin |
| Q41810114 | In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. |
| Q64119930 | Incidence and spectrum of yeast species isolated from the oral cavity of Iranian patients suffering from hematological malignancies |
| Q37719545 | Interactions between antifungal and antiretroviral agents |
| Q34045450 | Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients |
| Q36270118 | Management of invasive fungal infections in neutropenic patients |
| Q51187346 | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. |
| Q36867925 | Micafungin activity against Candida albicans with diverse azole resistance phenotypes |
| Q37124868 | Micafungin for the prophylaxis and treatment of Candida infections |
| Q35026516 | Micafungin in the treatment of invasive candidiasis and invasive aspergillosis |
| Q36693843 | Micafungin: a new echinocandin antifungal |
| Q37288766 | Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections |
| Q38053482 | Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections |
| Q34015567 | Micafungin: a sulfated echinocandin |
| Q27014780 | Micafungin: an evidence-based review of its place in therapy |
| Q36120798 | Micafungin: pharmacology, experimental therapeutics and clinical applications |
| Q36140652 | Micafungin: the US perspective |
| Q36222041 | New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients |
| Q36597431 | New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage |
| Q37079085 | Oesophageal candidiasis in elderly patients: risk factors, prevention and management |
| Q30391927 | Opportunistic infections in HIV disease |
| Q33746435 | Oropharyngeal candidiasis in the era of antiretroviral therapy |
| Q52648077 | Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata. |
| Q33451082 | Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate |
| Q40083822 | Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease |
| Q44685491 | Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis |
| Q35959484 | Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature |
| Q37669740 | Review of the pharmacology and clinical studies of micafungin |
| Q38633105 | Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces |
| Q37827883 | Safety of micafungin in infants: insights into optimal dosing |
| Q34605679 | Systemic antifungal agents: an update of established and new therapies |
| Q46961708 | Systemic antifungals. Pharmacodynamics and pharmacokinetics |
| Q26751038 | The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections |
| Q36828156 | The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety |
| Q36742397 | The echinocandins |
| Q36626518 | The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications |
| Q36821383 | The use of caspofungin in HIV-infected individuals |
| Q46600220 | Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis |
| Q37544911 | Tissue penetration of antifungal agents. |
| Q57569097 | Toxicidad hepática de micafungina. ¿Es micafungina un fármaco seguro? |
| Q46224687 | Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation |
| Q50118613 | We can do better: a fresh look at echinocandin dosing. |
| Q46000235 | [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients]. |
| Q51175640 | [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis]. |
Search more.